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Compared with some other species, insulin dysregulation in equids is
poorly understood. However, hyperinsulinemia causes laminitis, a
significant and often lethal disease affecting the pedal bone/hoof wall
attachment site. Until recently, hyperinsulinemia has been considered
a counterregulatory response to insulin resistance (IR), but there is
growing evidence to support a gastrointestinal etiology. Incretin
hormones released from the proximal intestine, glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic peptide, aug-
ment insulin secretion in several species but require investigation in
horses. This study investigated peripheral and gut-derived factors
impacting insulin secretion by comparing the response to intravenous
(iv) and oral D-glucose. Oral and iv tests were performed in 22 ponies
previously shown to be insulin dysregulated, of which only 15 were
classified as IR (iv test). In a more detailed study, nine different ponies
received four treatments: D-glucose orally, D-glucose iv, oats, and
commercial grain mix. Insulin, glucose, and incretin concentrations
were measured before and after each treatment. All nine ponies
showed similar iv responses, but five were markedly hyperresponsive
to oral D-glucose and four were not. Insulin responsiveness to oral
D-glucose was strongly associated with blood glucose concentrations
and oral glucose bioavailability, presumably driven by glucose ab-
sorption/distribution, as there was no difference in glucose clearance
rates. Insulin was also positively associated with the active amide of
GLP-1 following D-glucose and grain. This study has confirmed a
functional enteroinsular axis in ponies that likely contributes to insulin
dysregulation that may predispose them to laminitis. Moreover, iv
tests for IR are not reliable predictors of the oral response to dietary
nonstructural carbohydrate.
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THE BIOLOGY OF INSULIN SECRETION and action and the disruption
of these processes are substantively investigated in both hu-
mans and laboratory animal models due to their expanding
impact on human health and economics (1). The consequences
of insulin dysregulation for animal production and companion
animal health are also emerging as important fields of research
(3, 22, 39). Despite its potential relevance to human metabolic
syndromes and insulin resistance (IR), equine metabolic syn-
drome (EMS) rarely proceeds to type 2 diabetes mellitus and is
poorly understood. Hyperinsulinemia causes laminitis in
horses, a common and often lethal disease affecting the pedal
bone/hoof wall attachment site (4, 14, 31, 38). Although there
are several triggers for laminitis (6), it is most commonly
associated with endocrine dysregulation [such as pituitary pars
intermedia dysfunction (PPID)] and/or the grazing of pastures
that are rich in nonstructural carbohydrates (NSC) (20).
Understanding why certain horses develop hyperinsulinemia
when others do not, even though they are fed the same diet, is
the key to preventing laminitis. It is largely accepted in many
species that IR develops secondarily to persistent stimulation
and subsequent downregulation of insulin receptors during
pancreatic overstimulation, usually in association with dietary
factors (28, 34). In horses, there is mounting evidence to
suggest a similar scenario occurs, with the existence of an EMS
phenotype that encompasses regional obesity and insulin dys-
regulation (19). It is also known that ponies tend to be more IR
than horses (26). Furthermore, fasting hyperinsulinemia is an
inconsistent finding in horses/ponies diagnosed with EMS,
which may support the theory that IR develops as a down-
stream event of insulin dysregulation and even then only in
some animals.
Traditionally, diagnostic tests for IR have employed intra-
venous glucose tolerance tests (IVGTT) and/or combined glu-
cose-insulin tests (CGIT), which are clinically more practical
although less precise, than gold standard tests such as the
euglycemic-hyperinsulinemic clamp. However, due to the rel-
ative difficulty of performing even these tests in a field envi-
ronment, modified oral glucose tests (OGTs) have become
increasingly popular with clinicians. In addition, demonstra-
tion of an excessive insulin response to oral glucose may be
more closely aligned with the paddock grazing situation, where
ingestion of pasture or grain high in NSC has been repeatedly
associated with an increased risk for laminitis (19). However,
OGTs do not provide a measure of IR, which is often assumed.
Nonetheless, in this paper we question whether IR is, in fact,
the most useful indicator of laminitis risk. Instead, we argue
that hyperinsulinemia is the critical factor, and that this may
originate not from a failure of peripheral glucose uptake but
from other, primarily gastrointestinal, causes.
Studies in other species have shown that the incretin hor-
mones glucagon-like peptide-1 (GLP-1) and glucose-depen-
dent insulinotropic peptide (GIP, previously gastric inhibitory
peptide), are released from the intestine following carbohy-
drate consumption and work in concert with glucose to aug-
ment pancreatic insulin release (5). The relative contribution of
incretins to insulin production varies considerably among spe-
cies, ranging from up to 70% in humans to almost zero in
obligate carnivores such as the cat (21, 40). To date, very few
studies have investigated enteroinsular signaling in the horse
(7, 11, 15, 35). Thus, the present study had two objectives.
First, we aimed to compare the insulin response when glucose
was delivered orally with the response seen following iv
delivery to determine whether the hyperresponsiveness to glu-
cose seen in some animals was dependent on, or independent
of, the route of glucose administration. Second, we sought to
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determine the extent to which incretins are associated with the
insulin hyperresponsiveness of some horses to oral NSC,
provided in the form of free glucose or a high-energy, grain-
based diet.
MATERIALS AND METHODS
Sample population and study design. In total, the study used 31
ponies owned by Queensland University of Technology. The group
contained various breeds (principally Shetland, Welsh, Connemara,
Australian, and mixed-breed), spanned a wide range of ages (8-25 yr)
and body weights (90–368 kg), and included both mares and geldings
(Table 1). The ponies were given routine vaccinations, dental care,
and antiparasitic drugs at least 2 wk prior to the study and were
subjected to biochemistry and hematology blood testing. Blood test
results were all within species-specific reference ranges for the tests
performed (data not shown). Diagnostic tests for PPID were not
specifically performed for this study. The study included three sepa-
rate experiments: 1) a comparison of the insulin response to oral and
iv glucose, using a cohort of 22 ponies; 2) a more detailed examina-
tion of the insulin and incretin responses to oral and iv glucose in
separate cohort of nine different ponies; 3) a comparison of the insulin
and incretin response to two commonly fed, commercial grain-based
diets, using the same nine animals.
All the ponies were housed individually in dry lots during study
periods, and for the 10-day acclimatization period preceding each
phase with ad libitum access to water. They received a daily mainte-
nance diet of 0.8% body weight (BW) lucerne chaff, 200 g of wheat
bran, and a vitamin and mineral nutrient balancer (Vitam, Interna-
tional Animal Health, Huntingdon, Australia) at 8 AM and 1% BW
lucerne hay at 5 PM for 1 wk preceding each experiment and on
nontest days during the study period. Nutritional analyses of the
dietary components are outlined in Table 2, and test diets varied as
outlined below. All treatments were performed at 8 AM after an
overnight fast. No feed refusals occurred during the study. Daily
access to a larger dry run was provided to pairs of ponies to facilitate
free exercise (1 h). Ethical approval for the study was granted by the
University Animal Ethics Committee (SVS/QUT-109/13 and 470/14).
Experiment 1: oral diet challenge vs. iv dynamic testing. Twenty-
two ponies were selected from a larger cohort of 50 animals that had
undergone a screening test for their oral response to dietary NSC 2–4
wk prior to experiment 1. This test involved feeding a highly palatable
mixture of oats, molasses, lucerne chaff, and D-glucose, which had
been formulated to provide 3.8 g NSC/kg BW in a single meal. This
NSC content was selected on the basis of a prior study (unpublished
data) that investigated dietary NSC concentrations that cause signif-
icant pancreatic stimulation without inducing laminitis. On the basis
of their insulin response to this oral diet challenge (90 IU/ml 2 or
4 h after feeding), the selected ponies were all considered to be insulin
dysregulated (Table 1). During the 3-wk experimental phase of
experiment 1, the ponies were all initially subjected to a repeat oral
diet challenge (as above) in groups of four ponies per day, followed
a week later by an intravenous CGIT. A randomized block design was
used to ensure an equivalent wash-out period between tests for all
ponies. Blood samples were collected via intravenous jugular cathe-
ters placed aseptically the evening before, and catheter patency was
maintained with heparinized saline. For the CGIT, glucose (150
mg/kg; Baxter Healthcare, Old Toongabbie, Australia) was adminis-
tered as a bolus via the indwelling catheter followed by insulin (0.1
IU/kg Humulin-R; Eli Lilly, Melrose Park, Australia).
Experiment 2: oral vs. iv D-glucose. The nine ponies used for
experiment 2 received a preliminary OGT 1 wk before the study
commenced. This entailed feeding a meal containing 0.3% BW
lucerne chaff, 200 g wet wheat bran (as carrier), and 1 g/kg D-glucose
powder (Sigma-Aldrich, Castle Hill, Australia) and collecting blood
samples for serum insulin and blood glucose analysis before and 2 h
after feeding. Based on their fasting glucose-to-insulin ratios (FGIR,
a proxy for insulin sensitivity, below 4.5 considered IR) and their
insulin responses to the OGT (80 IU/ml at 2 h considered exces-
sive) (9, 17), the ponies were classified as either hyperinsulinemic
(HI) or normoinsulinemic (NI) responders (Table 1).
During the subsequent experimental phase, a second OGT was
performed as described above but using a smaller quantity of D-glu-
cose for palatability reasons (0.75 g/kg), and the time taken for each
pony to consume the meal was recorded (part 1). Seven days later, the
same dose of D-glucose (Baxter Healthcare, 0.75 g/kg) was adminis-
tered iv via an indwelling catheter (Milacath, Vetquip, Castle Hill,
Australia) placed aseptically in the left jugular vein (part 2). The rate
of glucose infusion was individualized for each pony to match their
rate of feed intake during part 1. The ponies were concurrently fed the
same base diet without added glucose to ensure that the total energy
intake was equivalent in the two parts of the study. A series of blood
samples was collected for glucose, insulin, and incretin analysis as
described below.
Experiment 3: grain-based diets. The same nine ponies were used
for experiment 3, which involved the feeding of 0.3% BW lucerne
chaff mixed with one of two commercial grain-based diets at 0.2%
BW: oats or Workhorse mix (Riverina Stock Feeds, Australia). A
2-wk acclimatization period preceded experiment 3 to allow gastro-
intestinal adjustment to the grain-based diets and avoid neophobic
responses. During the study period, each pony was fed each concen-
trate twice, using a randomized, cross-over design, and the average of
the data values recorded for each test was used for data analysis.
Blood sampling for hormone analysis was as described below.
Table 1. Characteristics of ponies used in 3 experiments to examine the endocrine response to oral and iv D-glucose
Exp. Group n Sex Age, yr BW, kg BCS, /9 CNS, /5 FGIR 2-h Insulin, IU/ml
1 22 12 F; 10 M 15.9  1.2 227  20 7.1  0.3 3.1  0.2 0.5–42 166 13
2 & 3 NI 4 1 F; 3 M 11.8  2 284  24* 6.5  1.0 1.3  0.8#  10 19.6 2.4*
2 & 3 HI 5 3 F; 2 M 13  3.3 172  7 7.4  0.5 2.6  0.5  4.5 110 16
Data are means  SE. BCS, body condition score; BW, body weight; CNS, cresty neck score; FGIR, fasting glucose-to-insulin ratio; F, female; HI,
hyperresponsive to oral glucose; M, male; NI, normal insulin response to oral glucose, *P  0.05, #P  0.1 HI vs. NI groups.
Table 2. Feed analyses of dietary components
Diet Lucerne Chaff Lucerne Hay Wheat Bran Whole Oats Workhorse Mix Molasses
DE, MJ/kg DM 10.1 9.6 12.7 11.8 13.2 —
WSC, % 8.0 4.2 — 3.0 6.4 23.6
Starch, % 2.0 2.0 16 33 32 34
CP, % 24.4 24.6 16.6 11.8 13.0 6.6
DE, digestible energy; DM, dry matter; WSC, water-soluble carbohydrate; CP, crude protein.
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Samples. In experiment 1, blood samples (5 ml) for the oral diet
challenge were collected just before feeding and then after 2 and 4 h
for immediate blood glucose and retrospective insulin analyses. Blood
samples (0.1 ml) for the CGIT were collected at 0, 1, 5, 15, 25, 35, and
45 min and then every 15 min for up to 2.5 h for immediate blood
glucose analysis. Serum insulin concentration was analyzed retrospec-
tively in samples (5 ml) obtained at 0, 45, and 75 min. In experiments
2 and 3, blood samples (5 ml) were collected at the following time
points after the provision of each test diet: 0, 15, 30, 60, 90, 120, 180,
240, and 360 min for immediate blood glucose analysis and retro-
spective insulin and incretin analyses.
The blood samples were divided equally between plain and
prechilled EDTA-coated tubes. Plain tubes were left to clot for 30
min, while EDTA tubes were placed on ice for 10 min prior to
centrifugation (10 min, 1,500 g). Aliquots (1 ml) of serum and plasma
were frozen rapidly and stored at 80°C until analyzed for insulin
(serum) and incretin (plasma) concentrations. Blood glucose concen-
tration was analyzed immediately using a hand-held glucometerg
previously validated by the investigators for equine blood against the
hexokinase method (data not shown).
Sample handling: incretins. It has been reported that GLP-1 and
GIP are less stable than many other hormones (5), so our processing
methodology was examined to determine the likelihood of any sig-
nificant degradative activity by the enzyme dipeptidyl peptidase-4
(DPP-4) in the plasma (EDTA) samples. Blood samples (24 ml) were
obtained from 10 of the ponies used in experiment 1 60–90 min after
feeding, and each sample was divided equally among eight prechilled
tubes: four tubes containing EDTA and four containing EDTA plus a
proprietary cocktail of protease inhibitors, including a DPP-4 protease
inhibitor (P800 tubes; Becton-Dickinson, North Ryde, Australia). All
eight tubes were placed on ice immediately, and one tube of each type
was removed from the ice after 10, 30, 60, and 120 min. Once
removed, the tubes were immediately centrifuged (10 min, 1,500 g),
and the plasma was harvested, rapidly frozen, and stored at 80°C
until analyzed for GLP-1.
Assays. Serum insulin concentrations were measured by a commer-
cial diagnostics laboratory using a chemiluminescent assay (Immulite
200; Siemens, Bowen Hills, Australia) (experiment 1) or in-house
using a validated ELISA (Mercodia, Uppsala, Sweden) (experiments
2 and 3). Equine-specific assays are not available for any incretin
hormone. Based on sequence homology, ELISAs (EZHGIP54K,
EZGLPHS35K, EZGLP1T36K; Millipore, Abacus ALS, Meadow-
brook, Australia) with anti-human capture antibodies against active
GLP-1 (7–36 amide), total GLP-1, and GIP were selected for evalu-
ation (Table 3). Assay specificity could not be determined accurately
due to a lack of equine-specific standards. Pooled equine samples
expected to contain incretin hormone concentrations in the high and
mid-to-low range (based on fed state and metabolic status) were
assayed in duplicate for all ELISAs. The assays were assessed for
cross-reactivity with equine plasma, precision (intra-assay CV for 6
replicates of the pooled samples), and accuracy [linear dilution (r2) of
pooled samples diluted with assay buffer 1:1, 3:4, 1:2, and 1:4].
Interassay CV was calculated for the validated assays. Recovery after
the addition and overnight incubation of a midrange assay standard
was assessed for each pooled sample and was used as an indicator of
potential assay interference.
Glucose kinetics analysis. The results obtained in experiment 2
demonstrated marked variability in blood glucose concentrations
between different animals fed the same diet. To determine whether
this reflected a difference in glucose absorption/distribution or clear-
ance rates, the clearance rates were estimated from the data obtained
after iv glucose infusion. This was done employing a population
pharmacokinetic (PK) analysis of the glucose concentration-time data,
using a nonlinear, mixed-effects modeling approach.
Glucose concentrations were modeled as a nonlinear function of
horse-specific PK parameter values whose distribution around the
population mean was specified as a level of hierarchy in the model. No
prior information was included in the data analysis. The PK analysis
was undertaken using the SAEMIX package of the R software
program (13). This package computes the maximum likelihood esti-
mator of the population parameters using the stochastic approximation
expectation maximization algorithm (30). Models were parameterized
in terms of the natural logarithm of the parameter values [e.g.,
ln(CL/F)].
Model selection was based on the deviance value (2 log likeli-
hood). In the absence of any prior information, models with smaller
deviance are preferred. However, some penalty for model complexity
was also considered. To facilitate this, for models with the same
random effects structure, the Akaike information criterion (2) and the
Bayesian information criterion (36) were evaluated and used to decide
between a one- or two-compartment model and between an additive,
proportional, and combined (additive with proportional) error struc-
ture. For covariate modeling, scatter plots showing the relationship
between estimated random effect values for relevant parameters and
covariates (such as weight) were visually inspected to determine
potential for covariates being included into the model.
Given the small sample size, body weight (kg) was the only
covariate considered for inclusion in the model. If a trend with PK
parameters was seen, then weight was considered for inclusion into the
final model using the following relationship: _i1	 z_i^2	 exp(
_i);
where _i are the individual values of clearance, 1 represents the
population value of the parameter, and 2 denotes the effect of z_i
being horse-specific covariate values normalized to have a mean of 0
and a variance of 1. The decision about whether a covariate should
appear in the final model was based on the decrease in the deviance
value and also the decrease in the (unexplained) between-horse
variability (BHV) of the relevant PK parameter. Decreases in both of
these would need to be of reasonable size to warrant the inclusion of
a given covariate.
Statistical analyses. All remaining data were analyzed using para-
metric tests, as the data were distributed normally (Shapiro-Wilk test).
Concordance between values for GLP-1 obtained in samples collected
Table 3. Assay characteristics of 3 ELISA kits used to measure incretins GLP-1 (total and active) and GIP in equine plasma
Assay Capture Antibody Precision CV, % Accuracy, % Linearity (r2) Interassay CV, % Limit of Detection, pM
tGLP-1 Anti-GLP- 1.6 0.95
High 1 human 10.1 88 0.99
Low polyclonal 10.1 71.4 0.97
aGLP-1 Anti-GLP- 9.7 0.14
High 1 human 6.0 88.0 0.99
Low polyclonal 10.7 80.0 1.00
GIP Anti-GIP 9.1 1.83
High human 5.9 106 0.98
Low monoclonal 8.1 93.8 0.99
Limit of detection (LOD) as stated by the manufacturer, not the actual LOD for equine plasma. Suggested conservative LOD for GIP kit is 18.3 pM for equine
plasma. GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic peptide; CV; coefficient of variation.
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with or without a DPP-4 inhibitor was determined using the Bland-
Altman method. Data from the iv and oral tests were compared with
a paired t-test. AUC was calculated using the trapezoidal method.
Given that glucose clearance and administered dose (iv and oral) did
not differ, the percent glucose bioavailability was calculated as F 
100 	 AUCoral/AUCiv. Correlation coefficients were estimated using
Pearson’s test, and linearity was determined by simple linear regres-
sion. The independent effects of mode of glucose administration and
metabolic status of the ponies, and the existence of any interaction
between these two factors, were determined for each hormone using a
two-way ANOVA. The contribution of several independent variables
(glucose and incretin concentrations) to insulin secretion observed during
the oral test was examined with multiple linear regression. Differences in
hormone response between diet types were assessed with one-way
ANOVA. Data were analyzed using SigmaPlot v. 12.5 and are reported
as means  SE. Significance was set at P  0.05.
RESULTS
Experiment 1: oral diet challenge vs. dynamic testing. The
22 ponies used in this study were considered to be insulin
dysregulated (or HI) based on excessive insulin responses to
oral NSC. All the ponies had insulin concentrations of 94
IU/ml 2 or 4 h after feeding a high-energy meal, with a mean
insulin concentration at 4 h of 214  24 IU/ml. When this
group was subjected to a CGIT, mean values for insulin at 45
and 75 min were relatively high (105  22 and 44  13
IU/ml, respectively), and the AUC insulin (AUCi) showed a
positive correlation with the AUCi obtained from the oral diet
challenge (r2  0.58, P  0.004).
However, when the ponies were examined on an individual
basis, applying standard cut-off values (18) for the diagnosis of
IR (positive phase glucose duration 45 min, serum insulin
not returned to baseline by 75 min), only 15 ponies in this
cohort were deemed to be IR. Thus, seven ponies showed a
dysregulated response to oral NSC but would not have been
diagnosed as IR and, hence, at risk of laminitis, if no oral test
had been performed. These results are consistent with the
hypothesis that insulin dysregulation may precede IR or may
occur independently of IR.
Experiment 2: insulin and glucose responses to D-glucose,
oral vs. iv administration. In experiment 2, insulin and glucose
responses to iv D-glucose administration were more marked
than following oral consumption (Fig. 1, A and B). This was
readily apparent when the AUCs were compared for the iv and
oral routes for insulin (442  40 vs. 288  64.6) and glucose
(73.6  3.78 vs. 43.6  3.15), respectively (P  0.05). Mean
oral glucose bioavailability was 60  4.9%. Of particular note
is the strong correlation between the AUCs for insulin and
glucose following the OGT (P 0.05), which was not the case
following iv D-glucose administration (Fig. 1, C and D).
Although the number of ponies used in this experiment was
small, dividing the group into HI and NI animals based on
FGIR and a previous OGT was very revealing (Fig. 2). When
the D-glucose was administered orally, insulin concentrations
were much higher in the HI group (P 0.05), as expected (Fig.
2A). However, when the glucose was administered iv, all the
ponies showed a similar glucose and insulin response (Fig. 2,
A and B).
The reason for the marked difference in insulin response
between HI and NI ponies following oral glucose can be
explained in part by examining the blood glucose response. In
particular, HI ponies demonstrated a larger AUC for glucose
and a higher insulin-to-glucose ratio than NI ponies following
this test (Fig. 2C). The oral bioavailability of glucose was also
higher in the HI group than in the NI ponies (67.4  6.9 vs.
51.1  3.6%; P  0.048). Overall, insulin and glucose con-
centrations were both affected by the method of D-glucose
administration (P  0.01 and P  0.001, respectively) and
metabolic status (P  0.01 and P  0.07, respectively), with
no significant interaction between these factors.
Fig. 1. Insulin and glucose responses to oral
and intravenous (iv) D-glucose in 9 ponies.
Serum insulin (A) and blood glucose (B)
concentrations were higher when D-glucose
(0.75 g/kg) was administered iv route (Œ)
than the oral route (). AUC for insulin
correlated with AUC glucose for the oral test
(C) but not for the iv test (D).
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Experiment 2: modeling glucose kinetics. As glucose bio-
availability seemed to be a distinguishing feature between HI
and NI ponies, glucose kinetics were investigated further to
establish whether this might have been due to differences in
glucose absorption and/or glucose clearance rates. Initially, a
one-compartment infusion model with the three error structures
was fitted to the data. The combined error structure provided
the smallest values of deviance (Table 4); however, signifi-
cantly smaller deviance values were observed for the two-
compartment models, with the proportional and combined
error structures giving small deviance values (Table 4). As the
combined error structure had an additional parameter com-
pared with the proportional error structure, the latter model was
selected and used for further analysis.
Covariate relationships were investigated for all parameters
and the covariate weight. There appeared to be linear relation-
ships between the random effect values and weight for all
population parameters. Hence, weight was considered as a
covariate to reduce the BHV of all parameters. Having weight
on CL/F and V1/F significantly reduced the deviance and
yielded similar values (Table 4). Consequently, weight on both
of these parameters was considered, which again significantly
reduced the value of deviance.
To investigate whether weight should be included in the
model on these parameters, the reductions in BHV were also
considered. With and without weight in the model, the BHV of
CL/F was 0.019  0.016 and 0.20  0.098, respectively,
similarly, for V1/F: 0.21  0.138 and 4.8e-6  0.028. There-
fore, including weight reduced the unexplained BHV for CL/F
and V1/F and was thus included in the final model. The
updated data revealed no trends with weight for either of these
parameters. Trends were still observed for Q/F and V2/F.
However, these were not investigated due to the small sample
size considered in this study.
In summary, the model providing the best fit for these
glucose data was a two-compartment infusion model with a
proportional error structure and with the inclusion of weight as
a covariate predictor for individual values of CL/F and V1/F.
The estimated PK parameters from the final model are shown
in Table 5. Individual predicted and observed concentrations
and individual predicted versus observed concentrations are
shown in Figs. 3 and 4, respectively. A plot of the distribution
of the residuals is shown in Fig. 5.
The relationship between individual values of CL/F and the
HI/NI grouping was investigated based on individual estimates
of clearance from the final model for the PK data. No trends for
CL/F and V1/F were detected. However, potential trends were
observed for Q/F and V2/F. Acknowledging that there was a
difference in mean body weight between the HI and NI groups,
and after adjusting for this factor in the model, we concluded
that no difference was seen in glucose clearance rates between
the HI and NI groups in this study. Accordingly, we conclude
that the higher glucose concentrations reached in HI ponies
were either a result of enhanced glucose absorption, or due to
differences in the first-pass effect of the liver.
Experiment 2: incretin assay validation. Three incretin as-
says demonstrated sufficient cross-reactivity to be used with
equine serum, presumably due to the conserved nature of
incretin structure. Values for assay precision and recovery
were acceptable, and all the assays showed good linearity
(Table 3). The kits showed good sensitivity relative to the
incretin concentrations measured in the pooled samples col-
lected after feeding, but for prefeeding baseline samples, con-
centrations of GIP were below the limit of detection in several
Fig. 2. Insulin and glucose responses to oral and iv D-glucose in 9 ponies differed according to metabolic status and route of D-glucose administration. Insulin
(A) and glucose (B) responses to iv D-glucose were similar in ponies classified as hyperinsulinemic (HI; ) and those that were normoinsulinemic (NI; o) ponies.
However, HI ponies () demonstrated a greater insulin (A) and glucose (B) response to oral D-glucose, than NI ponies (). C: AUC for the insulin-to-glucose
ratio was also greater in HI (filled bars), than NI (open bars) ponies for the oral test (OGT) but not the iv test (IVGT). *P  0.05.
Table 4. Deviance values for 11 different models describing
the pharmacokinetics of glucose following iv infusion of
D-glucose (0.75 g/kg) in 9 ponies
Model Deviance
1-cpt infusion with additive residual error 1,031.41
1-cpt infusion with proportional residual error 1,438.66
1-cpt infusion with combined residual error 1,028.66
2-cpt infusion with additive residual error 958.44
2-cpt infusion with proportional residual error 929.48
2-cpt infusion with combined residual error 929.22
2-cpt infusion with proportional residual error  weight
on CL/F 912.08
2-cpt infusion with proportional residual error  weight
on Q/F 919.70
2-cpt infusion with proportional residual error  weight
on V1/F 913.16
2-cpt infusion with proportional residual error  weight
on V2/F 920.77
2-cpt infusion with proportional residual error  weight
on CL/F & V1/F 896.06
CL/F; oral clearance, Q/F; bioavailable intercompartmental clearance, V/F;
compartmental volume of distribution after oral administration.
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instances. Diluting the standards supplied with the kit in an
attempt increase the detection range was not successful. Fur-
thermore, when samples in the low range were assayed, vali-
dation parameters for the GIP kit were not acceptable. Thus,
for the GIP kit, we suggest a conservative limit of detection of
18 pM.
When plasma samples were collected without a DPP-4
inhibitor, the mean GLP-1 concentrations were numerically
lower at all time points. However, this apparent difference was
small and not statistically significant. Furthermore, there was
no significant decrease in GLP-1 concentrations over time
(Fig. 6), suggesting that the results obtained from samples
collected using EDTA tubes are valid.
Experiment 2: incretin responses to D-glucose, oral vs. iv
administration. Total GLP-1 concentrations declined from
baseline during both iv and oral D-glucose tests, returning to
pretest levels within 6 h only for the iv test (Fig. 7A). Further-
more, tGLP-1 concentration was lower 30–120 min after iv
D-glucose compared with oral consumption. By contrast,
aGLP-1 increased from basal values in both tests, with a
bimodal (30 and 90–120 min) pattern of secretion (Fig. 7B).
The ratio of active to total GLP-1 had increased tenfold by 90
min after oral D-glucose (2.3% vs. 23%).
A positive GIP response was also observed, although a
bimodal pattern of secretion was not detected and GIP release
following the iv test appeared negligible (Fig. 7C). Based on a
comparison of AUCs following oral and iv glucose, both the
aGLP-1 and GIP responses were greater for the oral test (Fig.
7D). Neither AUC for aGLP-1 nor GIP was correlated with
AUCi for the iv test. However, AUCaGLP-1, but not AUCGIP,
was correlated with AUCi for the oral test (r2  0.66, P 
0.05). Overall, the independent contributions of glucose (P 
0.01), aGLP-1 (P  0.05), and GIP (P  0.56) to the variabil-
ity in insulin secretion for the oral test were 75.5, 22.7, and
1.7%, respectively.
The pattern of aGLP-1 secretion also differed between
pony subgroups for the two modes of D-glucose administra-
tion (Fig. 8A). The AUCaGLP-1 was greater (P  0.05) in HI
ponies than in NI ponies for both the oral (21.7  6.3 vs.
7.6  2.3) and iv tests (11.0  3.1 vs. 1.4  0.2),
respectively. However, for GIP, although a similar trend
was apparent between groups, the results were not signifi-
cant (Fig. 8B). Overall, aGLP concentration was affected by
metabolic status (P  0.01) and arguably the route of
glucose administration (P  0.06), whereas GIP levels were
influenced by route of administration only (P  0.01). No
significant interactions were found between metabolic status
and route of glucose administration.
Experiment 3: responses to grain. Insulin and aGLP re-
sponses over time were not affected significantly by the type of
grain supplied in the two different diets (Fig. 9, A and B), and
based on the AUC they were similar to the response seen with
oral D-glucose, showing a marked difference (P  0.05)
between HI and NI ponies (Fig. 9, D and E). For GIP secretion,
there was still no significant difference between the diets
across all nine ponies (Fig. 9C), no difference between the
HI and NI groups following oral D-glucose, and only a trend
toward a difference between these groups (P  0.1) for both
diets (Fig. 9F).
DISCUSSION
This study has demonstrated that IR is not a prerequisite for,
nor necessarily a precursor to, the hyperinsulinemia that may
predispose horses to laminitis. Instead, our results are consis-
tent with the hypothesis that gastrointestinal factors are key to
insulin dysregulation, due in part to incretin hormone release
(chiefly aGLP-1), but also to the fact that ponies with excessive
insulin responses to oral NSC absorb more glucose from their
diet or metabolize less during first pass through the liver than
normal ponies.
Data to support the theory that insulin dysregulation in
horses/ponies can occur independently of tissue resistance to
insulin was obtained in experiment 2, where the insulin re-
sponse to iv glucose did not discriminate between ponies that
were clearly HI or NI based on the oral test. Data from
experiment 1, where only 68% of HI ponies were also IR may
further support this theory. Although the correlation between
insulin data for the two tests used in experiment 1 might
indicate that oral tests are a good early predictor of insulin
insensitivity and is consistent with findings of correlation
between oral and iv tests in other studies (8), it may also
suggest that the CGIT simply has lower specificity than the
OGT. The current data suggest that oral tests should be an
important part of field-based diagnostics for veterinarians, with
less emphasis placed on simple iv tests for insulin sensitivity.
However, iv tests will remain useful for evaluation of more
advanced disease.
If it is accepted that insulin dysregulation may have a
gastrointestinal etiology, then it is important to elucidate the
factors that contribute to this, as these factors ultimately
demarcate HI ponies from normal ones. Insulin and glucose
concentrations and glucose clearance were closely aligned in
all ponies following iv D-glucose irrespective of metabolic
status. However, during the oral test, whereas HI ponies
responded with comparable magnitude to the oral and iv doses
Table 5. Parameters estimated from a 2-compartment model used to describe the pharmacokinetics of glucose following iv
infusion of D-glucose in 9 ponies
Parameter Estimate SE CV, %
CL/F (dl/h) 0.0915 0.00504 5.51
Q/F (dl/h) 0.3824 0.06479 16.94
V1/F (dl) 0.0023 0.00016 16.94
V2/F (dl) 0.2130 0.0320 15.04
2_CL, 2_V1 0.4319, 0.4919 0.0567, 0.0748 13.12, 15.20
BHV 2.1e-2, 2.1e-1, 4.8e-6, 1.9e-1 0.014, 0.121, 0.028, 0.096 66.12, 57.14,1000, 50.87
Proportional error 0.1721 0.00022 0.13
BHV, between-horse variability.
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of D-glucose, NI ponies barely registered a response to oral
D-glucose. The mechanism underlying the different insulin
responses to oral D-glucose between groups was demonstrated
to be due, in part, to an incretin effect. Both aGLP-1 and GIP
contributed to insulin secretion in an additive manner to glu-
cose, with glucose remaining the primary driver of insulin
secretion. The importance of glucose was established four
ways in the present study: by a simple comparison of blood
glucose concentrations in HI and NI ponies following the
OGT; by comparison of glucose bioavailability drawing on
Fig. 3. Individual predicted (-) and observed
() concentrations of glucose for 9 ponies
given a D-glucose (0.75 g/kg) infusion. Pre-
dicted values were based on a 2-compartment
model with a proportional error structure.
Body weight was included in the model as a
predictor for individual values of CL/F (oral
clearance) and V1/F (compartmental volume
of distribution after oral administration).
Fig. 4. Population and individual predicted values of
glucose as measured in 9 ponies after a D-glucose
infusion, based on a 2-compartment pharmacokinetic
model with a proportional error structure and body
weight as a predictor of individual values of CL/F and
V1/F vs. observed concentrations.
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OGT and iv data; by multivariate analysis, which included
incretin hormones in the model; and by a detailed glucose
kinetics analysis, which estimated glucose clearance rates. We
acknowledge that these data should be treated with some
caution due to the small number of observations and
the potential for the results to be confounded by time due to the
sequential design of the experiment. Furthermore, studies to
examine the first-pass hepatic clearance of glucose are required
to elucidate the effect of hepatic IR on glycemia in ponies.
Nevertheless, our data suggest that a focus on enteroendocrine
signaling is warranted in the quest to treat or prevent equine
hyperinsulinemia.
It should be noted that when performing the iv experiment
we attempted to mimic both the total energy provided to the
animals (by providing the base diet as part of the test) and the
rate of glucose delivery into the blood by pacing the infusion
rate to match the rate of feed consumption. However, despite
this, the iv infusion resulted in much higher blood glucose
levels than oral delivery, which masked the incretin effect.
Thus, a significant amount of orally administered D-glucose
was either not absorbed or, as is the case in other species, was
substantially removed during its first pass through the liver
before reaching the systemic circulation (12, 25). Either way,
the result was an unexpectedly low bioavailability of oral
glucose.
Glucose bioavailability can be affected by gastric emptying
rate, intestinal absorption, incretin biology, and hepatic extrac-
tion (25). Studies have demonstrated that rates of glucose
transport across the intestine can be affected by metabolic
dysfunction, with increased sodium-glucose cotransporter den-
sity associated with increased glucose absorption in obese
people (32). Similarly, glucose uptake and cotransporter ex-
pression were upregulated following 2 mo on a high-energy
diet in horses compared with a pasture-based diet (16). Fur-
thermore, slower rates of glucose absorption enhanced the
effectiveness of insulin and glucose disposal (27), which could
explain the subdued glucose responses to oral D-glucose in NI
ponies. Thus, the potential exists for intestinal glucose trans-
port to play an important role in equine metabolic disease. As
such, further studies in horses to investigate glucose uptake and
sensing in the proximal intestine, incretin action, and feedback
mechanisms, as well as enteroendocrine cell distribution, are
warranted.
In addition to responding to glucose, pancreatic insulin re-
sponse is also augmented by incretin hormone release in several
species (5). The present study has demonstrated a strong associ-
ation between aGLP-1 and the insulin response to oral NSC,
estimating that almost 23% of the variation in insulin concentra-
tions can be explained by the variation in aGLP-1 concentrations.
Thus, this study has achieved the second objective of demonstrat-
ing, and partly quantifying, an incretin response. The pattern of
aGLP-1 secretion following oral D-glucose in ponies was similar
to that seen in humans, where a comparable dose of glucose also
resulted in the biphasic release of aGLP-1 over a similar time
Fig. 5. Distribution of population weighted residuals, individual weighted residuals, and normalized prediction distribution errors for a 2-compartment
pharmacokinetic model of glucose metabolism in 9 ponies.
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frame (24). There was no aGLP-1 response to iv glucose in
humans, and the small response observed in the present iv study
can be explained by the concurrent provision of a small, low-
glycemic meal to the ponies.
Although GLP-1 showed a significant association with post-
prandial insulin concentrations in horses, the influence of
incretins in this species may not be as great as in humans,
where they can account for up to 70% of postprandial insulin
release (41). Furthermore, the ponies used in the present study
showed a higher insulin response to iv D-glucose than orally
consumed D-glucose, whereas the converse has been shown to
occur in humans (23). There are limited data to draw on from
other equine studies, but GLP-1 was reported to have a smaller
effect on insulin secretion than glucose in a single pony (7).
The negative response of tGLP-1 was potentially related to an
increased rate of amide degradation and the conversion of tGLP-1
to aGPL-1. The ratio of active to inactive forms of the peptide
increased tenfold as a consequence of oral D-glucose ingestion.
The mean values for basal concentrations of aGLP-1 in ponies
covered a larger range than that seen in healthy humans (0.1 to 1.5
vs. 0.4 to 1.4 pM), with the low fasted values seen in NI ponies
being comparable to those seen in patients with type 1 diabetes (0
to 1.9 pM) (24, 44). However, peak aGLP-1 concentrations in
ponies following oral D-glucose were lower than those recorded in
Fig. 6. Active glucagon-like peptide-1 (a)GLP-1 concentrations in samples of pony plasma collected in tubes containing either EDTA alone or EDTA plus a
proprietary cocktail of protease inhibitors, including a dipeptidyl peptidase (DPP)-4 inhibitor (P800 tube). A: concentrations of aGLP-1 did not differ significantly
between collection tubes or over time if samples were kept on ice and processed rapidly. B: comparison of both sampling methods using linear regression. C:
Bland-Altman analysis revealed no meaningful difference between the 2 methods: bias  0.856, SD  2.12, limits of agreement  3.297, 5.009, bias 95%,
CI  0.179–1.533, lower LOA 95% CI  4.469  2.124, upper LOA 95% CI  3.836  6.182.
Fig. 7. Incretin responses to oral and iv
D-glucose in 9 ponies. A: mean total GLP-1
(tGLP-1) decreased from basal values fol-
lowing both oral () and iv (Œ) D-glucose
(0.75 g/kg) administration. B: however,
mean aGLP-1 concentrations increased from
basal values, with a larger increase 30–90
min after oral () D-glucose vs. increase
after iv (Œ) D-glucose. C: mean glucose-
dependent insulinotropic peptide (GIP) con-
centrations were increased at all time points
after oral () D-glucose consumption vs.
small increase 30–120 min after iv (Œ) D-
glucose administration. D: accordingly,
mean AUC was greater over the 6 h after
oral (filled bars) D-glucose consumption for
aGLP-1 and GIP but not tGLP-1 vs. iv (open
bars) D-glucose administration. *P  0.05.
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humans (4.16 1.36 vs. 10 to 12 pM) and in two previous studies
using horses (15 to 25 pM), albeit following a much larger oral
NSC load (7, 24).
There was a marked GIP response following oral glucose in
the present study, but a comparison of GIP dynamics between
species is not as closely aligned. We did not observe the
biphasic mode of secretion with an early peak at 4–45 min
reported in humans (24), although our lower sampling fre-
quency could account for this. Moreover, the GIP concentra-
tion range observed in the present study (20 to 37 pM) was
lower than that reported in a previous study with horses and
ponies (44–133 pM), where a porcine radioimmunoassay was
used for GIP measurement (15). Nevertheless, our results do
confirm observations in other species (33) that GIP is secreted
in higher concentrations than GLP-1 following a meal.
Interestingly, despite the large GIP response, this incretin ac-
counted for much less of the variation in insulin levels than
aGLP-1. This is not consistent with the theory that both aGLP-1
and GIP contribute equally to the incretin effect (5). The
difference between the two incretins in the present study
was that GIP showed a marked though highly variable
response to oral glucose in the NI ponies, whereas aGLP-1
and insulin did not. Again, the small number of observations
requires caution when interpreting these data, but they are
nevertheless consistent with a study that compared ponies
(generally HI) with racehorses (generally NI) and found no
Fig. 8. Incretin responses to oral and iv D-glucose in 9 ponies differed according to metabolic status and route of D-glucose administration. A: mean aGLP-1
secretion was greater in ponies classified as HI () than NI () ponies for 30–180 min after oral D-glucose (0.75 g/kg) consumption. Similarly, the aGLP-1
response to iv D-glucose was higher in HI () ponies vs. a negligible response in NI ponies. Incretin responses following iv D-glucose are most likely associated
with consumption of the accompanying low-glycemic meal. B: mean values for GIP were not different between HI () and NI () ponies following oral D-glucose.
However, HI () ponies did have a larger GIP response to iv D-glucose for 30–60 min vs. NI ponies.
Fig. 9. Incretin responses to oral D-glucose vs. the 2 diets, oats or a commercial grain mixture (Workhorse mix, WHM) in 9 ponies. A: mean insulin concentrations
after consumption of oats () and WHM (Œ) did not differ over time, and the responses of aGLP-1 (B) and GIP (C) were similar for the 2 diets. When subdivided
according to metabolic status, HI ponies (filled bars) had a larger AUC for insulin (D) and aGLP-1 (E) following consumption of grain-based diets vs. NI ponies
(open bars). Furthermore, these responses to grain were similar to their previous responses to D-glucose (shown for reference). F: by comparison, GIP showed
no difference in response to D-glucose and only a trend toward a greater response in HI ponies to the grain-based diets. *P  0.05; #P  0.07.
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difference in their GIP response to oral glucose (15). Fur-
thermore, GIP has been reported to be less potent than
GLP-1 in stimulating insulin release in humans (29). Given
that GIP and GLP-1 do not appear to be cosecreted in other
species but have distinct secretion patterns (37), GIP may
have other important roles in horses, such as influencing fat
metabolism (42), or it may respond differently during insu-
lin dysregulation (10, 40).
As ponies rarely consume free glucose under normal hus-
bandry conditions, it was important to verify our results by
feeding more complex, high-energy diets and examining the
incretin response. This was also important as incretins are
known to respond to dietary components other than glucose,
including certain amino acids and fats (42, 43). The incretin
responses to the grain-based diets were consistent with the
results seen using free D-glucose, as a strong association was
seen between insulin and aGLP-1 concentrations, with a
weaker association for GIP. Although there was no clear
difference in response between the Workhorse mix and the
oats, further studies on different dietary components fed to
both horses and ponies could be enlightening, particularly as
recent studies have demonstrated differential responses to a
grain-based diet between horses and ponies (7, 35).
As with metabolic syndromes in other species, EMS is
complex and multifactorial. This study has demonstrated that
some ponies can be hyperresponsive to oral NSC without
attendant evidence of altered peripheral glucose uptake (IR) or
clearance rates. In particular, this study has provided evidence
for a functional enteroinsular axis in ponies, where alterations
in glucose absorption and the secretion of GLP-1 may account
for the difference between healthy and dysregulated ponies. A
“foregut theory” for equine insulin dysregulation has been
proposed and requires ongoing investigation, as further studies
into the mechanisms that control glucose absorption and those
that stimulate incretin release in the horse may prove beneficial
in preventing or treating laminitis.
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